Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease
08:00am, Monday, 23'rd Sep 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease.
Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
11:57am, Tuesday, 03'rd Sep 2024
AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.
Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock
09:50am, Wednesday, 21'st Aug 2024
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed t
5 Small Drug Stocks to Buy as Innovation Reaches Peak
09:20am, Friday, 16'th Aug 2024
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript
12:14pm, Friday, 09'th Aug 2024
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2024 Earnings Conference Call August 9, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief
Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics
10:30am, Friday, 09'th Aug 2024
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to
AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?
10:15am, Friday, 09'th Aug 2024
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
08:15am, Friday, 09'th Aug 2024
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.19 per share a year ago.
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q2 Earnings
10:20am, Wednesday, 07'th Aug 2024
Get a deeper insight into the potential performance of Amneal (AMRX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some o
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
11:01am, Friday, 02'nd Aug 2024
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) is a Great Momentum Stock: Should You Buy?
01:00pm, Monday, 29'th Jul 2024
Does Amneal Pharmaceuticals (AMRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
10:40am, Monday, 29'th Jul 2024
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Amneal (AMRX) Is Attractively Priced Despite Fast-paced Momentum
09:51am, Monday, 29'th Jul 2024
Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
11:40am, Wednesday, 10'th Jul 2024
Amneal Pharmaceuticals has seen a significant increase in its share price of >400% after hitting an all-time low in March 2023. The company reported record revenues in Q1 2024, with growth in all thre
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
04:05pm, Tuesday, 09'th Jul 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the launch of FOCINVEZ™, a ready-to-use injectable. Unlike other v
